From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• CAR-T therapy has transformed hematological cancer treatment.
• Solid tumors present unique challenges including heterogeneity and immunosuppression.
• Limited efficacy of current CAR-T therapy in solid tumors necessitates further research.

Purpose of the Study:

• To review challenges restricting CAR-T therapy in solid tumors.
• To highlight recent advancements and clinical potential in gastric cancer, liver cancer, and glioma.
• To explore innovative strategies for enhancing CAR-T efficacy.

Main Methods:

• Review of primary causes and challenges in solid tumor CAR-T therapy.
• Overview of advancements in CRISPR-edited and allogeneic CAR-T cells.
• Exploration of AI-driven target discovery, synthetic biology, and combination strategies.

Main Results:

• Early trials show promising clinical potential in gastric cancer, liver cancer, and glioma.
• CRISPR and allogeneic CAR-T cells aim to improve scalability.
• AI, synthetic biology, and combination therapies enhance specificity and persistence.

Conclusions:

• CAR-T therapy holds significant potential for treating aggressive solid tumors.
• Technological optimization and clinical refinement are crucial for future success.
• CAR-T therapy is poised to reshape precision oncology.